- Result of two randomized trials comparing nolatrexed (Thymitaq) versus methotrexate in patients with recurrent head and neck cancer. Pivot, X., Wadler, S., Kelly, C., Ruxer, R., Tortochaux, J., Stern, J., Belpomme, D., Humblet, Y., Domenge, C., Clendeninn, N., Johnston, A., Penning, C., Schneider, M. Ann. Oncol. (2001)